Stay updated on HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial

Sign up to get notified when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record is now displayed, including its eligibility criteria, treatment arms, study outcomes, locations, and record dates.
    Difference
    63%
    Check dated 2026-11-08T14:18:39.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:38:15.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    An NIH banner announces a website transition and says “Super Intelligence” is being used in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-25T16:28:43.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changes from v3.7.1 to v3.7.2; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:10:43.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The 403 Forbidden page remains unchanged in substance; its footer revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T22:07:35.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The study page for NCT04337658 now renders a 403 Forbidden error instead of displaying the study details, blocking access to the record; this is accompanied by a minimal header/footer indicating an access-denied page rather than the full study information.
    Difference
    21%
    Check dated 2026-09-20T19:46:42.000Z thumbnail image

Stay in the know with updates to HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the HER2 Therapy+Fulvestrant/Capecitabine in HR+/HER2+ MBC Clinical Trial page.